ASLAN Pharmaceuticals Limited Sees Large Growth in Short Interest - Defense World

ASLNDelisted Stock  USD 0.60  0.03  4.76%   
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
ASLAN Pharmaceuticals Limited Sees Large Growth in Short Interest Defense World

Read at news.google.com
Google News at Macroaxis
  

Aslan Pharmaceuticals Fundamental Analysis

We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Ratio

Current Ratio Comparative Analysis

Aslan Pharmaceuticals is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Aslan Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Aslan Pharmaceuticals Related Equities

NAMSNewAmsterdam Pharma   41.41   
0%
100.0%
ACRVAcrivon Therapeutics,   8.45   
0%
20.0%
CMPXCompass Therapeutics   7.88   
0%
19.0%
LYRALyra Therapeutics   5.00   
0%
12.0%
ANTXAN2 Therapeutics   2.65   
0%
6.0%
ANEBAnebulo Pharmaceuticals   0.64   
0%
1.0%
CGEMCullinan Oncology   0.24   
1.0%
0%
IVAInventiva   0.38   
1.0%
0%
ERASErasca   0.67   
1.0%
0%
AVTEAerovate Therapeutics   1.14   
2.0%
0%
GPCRStructure Therapeutics   1.30   
3.0%
0%
MLYSMineralys Therapeutics,   1.45   
3.0%
0%
CTMXCytomX Therapeutics   2.48   
5.0%
0%
ACHLAchilles Therapeutics   2.86   
6.0%
0%
IOBTIO Biotech   4.55   
10.0%
0%
AGIOAgios Pharm   5.76   
13.0%
0%
ASMBAssembly Biosciences   6.46   
15.0%
0%
TILInstil Bio   7.12   
17.0%
0%
GLUEMonte Rosa   9.85   
23.0%
0%
ADAGAdagene   16.21   
39.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Consideration for investing in Aslan Stock

If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bonds Directory
Find actively traded corporate debentures issued by US companies
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Transaction History
View history of all your transactions and understand their impact on performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Technical Analysis
Check basic technical indicators and analysis based on most latest market data